Relay Therapeutics (NASDAQ: RLAY) combines computational skills with experimental approaches across the fields of structural biology, biophysics, chemistry and biology. The integration of these disparate disciplines, tools, and cultures enables the company to design therapies against validated but previously intractable targets. Its initial discovery programs in cancer have led to the development of highly selective inhibitors of disease-causing proteins in genomically defined patient populations.